Tight control for Crohn’s disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial

OBJECTIVE: To evaluate the cost-effectiveness of an inflammatory biomarker and clinical symptom directed tight control strategy (TC) compared with symptom-based clinical management (CM) in patients with Crohn’s disease (CD) naïve to immunosuppressants and biologics using a UK public payer perspectiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Panaccione, Remo, Colombel, Jean-Frederic, Travis, Simon P L, Bossuyt, Peter, Baert, Filip, Vaňásek, Tomáš, Danalıoğlu, Ahmet, Novacek, Gottfried, Armuzzi, Alessandro, Reinisch, Walter, Johnson, Scott, Buessing, Marric, Neimark, Ezequiel, Petersson, Joel, Lee, Wan-Ju, D’Haens, Geert R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Inflammatory Bowel Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7063396/
https://www.ncbi.nlm.nih.gov/pubmed/31285357
http://dx.doi.org/10.1136/gutjnl-2019-318256

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7063396/
https://www.ncbi.nlm.nih.gov/pubmed/31285357
http://dx.doi.org/10.1136/gutjnl-2019-318256

Ejemplares similares